Cavan M. Redmond's most recent trade in Insight Molecular Diagnostics Inc. was a trade of 10,000 Common Stock, no par value done . Disclosure was reported to the exchange on June 24, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2022 | 10,000 | 120,863 (0%) | 0% | 0 | Common Stock, no par value | |
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2022 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Purchase of securities on an exchange or from another person at price $ 1.19 per share. | 16 Mar 2022 | 40,000 | 110,863 (0%) | 0% | 1.2 | 47,560 | Common Stock, no par value |
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 45,000 | 45,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnost... | Cavan M. Redmond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 18,416 | 70,863 (0%) | 0% | - | Common Stock |